Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Three Amigos Stock Thread -- Ignore unavailable to you. Want to Upgrade?

To: Sergio H who wrote (9203)	9/30/1998 12:30:00 AM
From: Amigo Mike	Read Replies (1) \| Respond to of 29382

Hi Amigo, I would submit USFS to you for perusal. I am thinking this one could double in 6 months. Amigo Mike

To: Sergio H who wrote (9203)	9/30/1998 8:36:00 PM
From: Amigo Mike	Respond to of 29382

Our little Antex has new this evening !!! AntexBiologics Licenses Seven NIH Patents on Carbohydrate Receptor Technology GAITHERSBURG, Md., Oct. 1 /PRNewswire/ -- AntexBiologics announced that it has licensed the rights to seven U.S. patents covering carbohydrate receptor technologies for bacteria and fungi from The National Institutes of Health ("NIH"). The NIH patents have claims to various carbohydrate receptors for both bacteria and fungi, as well as methods of using the carbohydrates as diagnostics and therapeutics. This licensing transaction is part of an ongoing effort to expand Antex's technology and product development programs. "Using ART(TM) (Adhesin Receptor Technology), the earliest comprehensive platform technology developed by the Company, Antex develops novel vaccines, anti-infective therapeutics, and diagnostics. Several of our vaccine candidates, including one now in clinical trials, were identified through ART. Acquiring the rights to these patented carbohydrate receptors adds to our receptor library and enhances our proprietary position," said Theresa M. Stevens, Vice President, Corporate Development, of Antex. "Including the patents from this license, Antex now owns or has rights to a total of 19 U.S. patents. To date, we have 77 patents worldwide, with 14 pending U.S. and corresponding worldwide applications," Ms. Stevens continued. To begin a mucosal infection, bacteria must first bind to an individual's cells that line the gastrointestinal, respiratory, or urogenital tracts, called "epithelial cells." Bacteria manage to link with these cells by using one or more molecules on the bacteria's surface -- known as adhesins -- that fit one of the epithelial cell's many receptors. These receptors can be molecules including glycolipids, phospholipids, proteins, and carbohydrates. With ART, Antex has identified specific receptors used by over 60 bacteria and toxins. From these identified receptors, Antex can identify, isolate and/or synthesize adhesin proteins that are useful as subunit vaccines, as targets for anti-infectives, and as diagnostic reagents. "The Company is actively pursuing additional opportunities to add to our therapeutic product portfolio by acquiring technologies, late-stage development candidates, and marketable products. We are also planning to regain rights to some of our own technologies applicable to AntexPharma that were previously licensed to others," said Dr. V.M. Esposito, CEO and President of Antex. AntexBiologics is a biopharmaceutical company dedicated to the discovery, development and commercialization of products to prevent and treat infectious diseases and related disorders. The Company has four vaccine products in clinical development and currently has strategic alliances with SmithKline Beecham, Pasteur Merieux Connaught, and the U.S. Navy. The Company's common stock is quoted on the OTC Bulletin Board under the ticker symbol ANTX. Statements contained herein that are not historical facts may be forward- looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company. Such factors are more fully described in the Company's Form 10-KSB filed with the United States Securities and Exchange Commission, and include, but are not limited to: (i) the Company's ability to successfully complete product research and development, including preclinical and clinical studies and commercialization; (ii) the Company's ability to obtain required governmental approvals; (iii) the Company's ability to attract and/or maintain manufacturing, sales, distribution and marketing partners; and (iv) the Company's ability to develop and commercialize its products before its competitors. SOURCE AntexBiologics CO: AntexBiologics; The National Institutes of Health; SmithKline Beecham; Pateur Merieux Connaught; U.S. Navy ST: Maryland IN: MTC SU: 09/30/98 17:44 EDT prnewswire.com

To: Sergio H who wrote (9203)	9/30/1998 9:01:00 PM
From: LTK007	Respond to of 29382

Amigos and Amigas does someone control this product--this could possibly be a quite hot item---it was a headliner on Yahoo!----so someoe can you find a stock that is deep into Neovastat--- Health Headlines Wednesday September 30 6:03 PM EDT Angiogenesis inhibitor boosts cancer drugs TORONTO, Sep 30 (Reuters) -- Early reports in both animal and clinical studies suggest that AE-941 (Neovastat), an angiogenesis inhibitor derived from shark cartilage, enhances the efficacy of drugs used to fight cancer, according to a new report. Researchers also say that the investigational agent reduces chemotherapy-related toxicity without adding significant toxicity of its own. At the joint meeting of the American College of Clinical Pharmacology, the Canadian Society of Clinical Pharmacology and the Royal College of Physicians and Surgeons of Canada, Dr. Marc Riviere, vice-president of clinical affairs at Aeterna Laboratories in Quebec City, Quebec, reported on tests of the drug in animal studies of lung cancer as well as results from clinical studies of patients with lung and prostate cancer. Neovastat is called an angiogenesis inhibitor because it prevents the formation of new blood vessels, a process critical to the growth and spread of cancer, Riviere explained. He noted that the inhibitor -- given orally in liquid form -- has been extensively tested in the mouse studies both alone and in combination with the cancer drug cisplatin. Based on several hundred animal tests, the Quebec group showed that on its own, Neovastat in doses of 500 mg/kg led to a 69% reduction in the number of lung surface metastases, with no associated weight loss or mortality. ''In the same mouse model, injection of cisplatin (3 mg/kg) resulted in a 54% reduction in the incidence of lung metastases,'' Riviere reported. Cisplatin given in higher doses, both 5 mg/kg and 10 mg/kg, achieved greater reductions in lung metastases of 80% and 90% respectively. But 7% of animals given the 5 mg/kg dose died and 27% of animals given the 10 mg dose died. By combining oral Neovastat with low-dose cisplatin (3 mg/kg), however, ''...we saw an 83% reduction in lung metastases, with none of the animals dying, which suggests that Neovastat enhances the anti-metastatic activity of cisplatin,'' Riviere told Reuters Health. All studies were done at the McGill University Health Centre in Montreal and involved at least 15 animals per group. Preliminary safety data from trials in advanced lung and prostate cancer also support the lack of serious toxicity associated with Neovastat use. Riviere reported that preliminary results of a study in a group of 77 patients with advanced metastatic disease taking a high dose of the drug suggest a similar safety profile to that seen in animals after 3 months of Neovastat use. And the drug appears to have slowed progression of cancer in these patients. ''These patients all had advanced disease and we did not expect to see a reduction in tumor size as there was no chemotherapy left for them,'' Riviere said. There was also a significant difference in analgesic consumption between those on high dose versus lower dose Neovastat. Fewer patients on high-dose Neovastat had to increase their morphine intake over the study interval compared with those on lower doses, who required increasing amounts of morphine. Studies using Neovastat in lung, prostate, and breast cancer are currently on-going in the US and Canada, with results from the advanced lung cancer trial expected by the end of the year. Meanwhile, the National Cancer Institute recently announced it would sponsor two trials using Neovastat in combination with standard anti-cancer treatment, one in patients with non-small-cell lung cancer and the second in either breast, prostate, or colon cancer patients.